Page 2 - Eli Lilly

Eli Lilly to pump $1 billion into India to boost contract manufacturing

The US pharma major to set up a manufacturing and supply hub in Hyderabad as part of a $1 billion investment aimed at boosting contract production in India

Eli Lilly to invest over $1 billion in India to boost manufacturing

Eli Lilly, which launched its obesity drug Mounjaro in India earlier this year, plans to invest $1 billion to strengthen manufacturing partnerships and set up a new Hyderabad facility

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

'Worst in Europe': Eli Lilly CEO slams UK drug prices, warns of fewer drugs

Eli Lilly CEO Dave Ricks slammed the UK's strict drug pricing rules, warning that the country risks losing new medicines and investment unless changes are made to its rebate scheme

After Mounjaro success, Eli Lilly plans to launch weight-loss pill in India

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16

Ozempic maker Novo Nordisk to cut 9,000 job to save $1.3 billion annually

Novo Nordisk will cut 11.5 per cent of its workforce to save costs and streamline operations as competition rises and sales of Wegovy and Ozempic slow, especially in the US market

Eli Lilly to raise UK price of weight-loss drug Mounjaro by 170%

The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September

Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy

Can Mounjaro transform obesity care? ₹50 crore sales in three months

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Demand for obesity drugs soars in India as Lilly, Novo jostle for mkt share

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst three globally for high obesity rates

Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

India approves Eli Lilly's Mounjaro pen for diabetes, weight control

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management

Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug

Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly's Mounjaro

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

The company plans to submit efsitora, its once-weekly insulin for type 2 diabetes, to global regulators by end-2026 following positive Phase 3 trial outcomes

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May

Eli Lilly to acquire gene-editing firm Verve Therapeutics for $1.3 billion

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond its blockbuster weight-loss and diabetes drugs

Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade

It logged value sales worth Rs 12.61 crore in May, compared to Rs 7.88 crore in April.

Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Why Ozempic maker Novo Nordisk is losing its lead in weight-loss drugs

The Danish drugmaker led the obesity revolution with Ozempic and Wegovy but now lags Eli Lilly in efficacy, trials, and strategy in a $150-bn market

Eli Lilly's tirzepatide shows superior weight loss to Novo's semaglutide

Phase 3b trial finds Lilly's tirzepatide delivers higher average weight loss and waist reduction than Novo's semaglutide in people with obesity or overweight